Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in classical Hodgkin Lymphoma
NCT02181738Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2014
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by Bristol Myers Squibb. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02181738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181738.